New drug cocktails aim to stop bile duct cancer return after surgery
NCT ID NCT07640048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants will receive one of three treatment combinations and be compared to historical data. The goal is to see which approach improves survival without recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab, gemcitabine, cisplatin, apatinib, S-1
What this could lead to
If successful, this could identify better post-surgery treatments to delay or prevent cancer recurrence in high-risk patients.
What could go wrong
This is a small, early-phase real-world study without randomization, so results may not be conclusive. Side effects from chemotherapy and immunotherapy can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital (PUMCH)
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••